openPR Logo
Press release

Systemic lupus erythematosus (SLE) Market - Global Industry Analysis 2017 - 2025

03-19-2018 02:38 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Systemic lupus erythematosus (SLE) Market - Global Industry

Systemic lupus erythematosus (lupus) is an autoimmune disease which is characterized by inflammation of tissue in the body. Immune response is directed toward the body’s own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the age group of 25 to 45. Although the main cause of the disease is unknown, it is linked to genetic and hormonal factors. In several instances, drug-induced lupus erythematosus is also observed commonly against drugs such as isoniazid, hydralazine, and procainamide. The diagnosis of systemic lupus erythematosus is based on distinctive clinical findings of the skin, kidneys, joints, the central nervous system, as well as on serological parameters such as antinuclear antibodies (ANA). Common symptoms include fever, fatigue, and arthralgia occurring at disease onset.  Joint swelling or a butterfly rash observed particularly in women of childbearing age indicates the development of systemic lupus erythematosus (SLE). 

Request Brochure of Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2006

The prevalence of lupus is higher in Europe and Australia as compared to North America. In North America, the disease is more prevalent among Hispanics, Asians, and Native Americans, according to Centers for Disease Control and Prevention (CDC). Currently no cure for lupus exists, but the disease is treated with immunosuppressants, anti-inflammatory drugs, and intravenous immunoglobulins. GlaxoSmithKline plc manufactured Benlysta (belimumab) is a B lymphocyte stimulator, which received FDA approval in 2011 for treatment of lupus. Ibuprofen and aspirin are widely prescribed anti-inflammatory drugs for suppressing symptoms of lupus. Immunosuppressants such as CellCept (Mycophenolatemofetil) by Roche, Neoral (Cyclosporine) by Novartis AG, and Imuran (Azathioprine) by GlaxoSmithKline plc are also commonly prescribed for lupus treatment. 

Request TOC of Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2006

The global systemic lupus erythematosus market is witnessing significant growth due to rising prevalence of the disease, medical advancements in the treatment of systemic lupus erythematosus or SLE, extensive research activities, and rising awareness among people about SLE treatments. The systemic lupus erythematosus market can be categorized on the basis of drug class and region. On the basis of drug class, the market can be segmented into non-steroidal anti-inflammatory drugs (NSAIDs), anti-malarial agents, corticosteroids and immunosuppressants. On the basis of geography, the market is segmented into five regions, namely North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

In terms of geography, North America accounts for the dominant share in terms of revenue owing to advancements in the treatment of systemic lupus erythematosus and rising awareness among people about the disease. Europe accounts for the second largest market in terms of revenue due to high incidence rate of SLE and increase in research activities in the field of systemic lupus erythematosus. The Asia Pacific market is also witnessing positive growth due to increase in number of people belonging to high income groups and increased government funding for research activities. Currently, major biotechnology companies are outsourcing their product development services to countries such as China, Singapore, Malaysia, and India, which is ultimately propelling the growth of the market in this region. Middle East, Latin America, and Africa are expected to be the prospective markets in the near future due to the high adoption rate of advanced medication and highly developing pharmaceutical and biotechnology industry. 

Some of the key players operating in the systemic lupus erythematosus (SLE) market include Aurinia Pharmaceuticals Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, ImmuPharma plc, Mylan N.V., F. Hoffmann-La Roche AG, and Sandoz International GmbH (Novartis AG).

Enquiry for discount on this report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2006

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Systemic lupus erythematosus (SLE) Market - Global Industry Analysis 2017 - 2025 here

News-ID: 983912 • Views: 277

More Releases from Transparency Market Research

POULTRY HEALTH MARKET SIZE, SHARE & TRENDS | INDUSTRY ANALYSIS REPORT, 2025
The poultry health market is set to see growth at an impressive CAGR (Compound Annual Growth Rate) of 7.6% between 2017 and 2025, owing to increasing levels of awareness regarding poultry diseases, owing to a recent study by Transparency Market Research. This will pull up the market share to a hefty USD 11 bn by the end of the forecast period; it is a steep rise from USD 5.7 bn
CRISIS-DRIVEN GROWTH OPPORTUNITIES DISPOSABLE SYRINGES MARKET
Disposable Syringes Market: Introduction According to the report, the global disposable syringes market was valued at US$ 6.9 Bn in 2019 and is expected to expand at a CAGR of ~7% during the forecast period from 2020 to 2030. A disposable syringe is made for one-time use. It is then disposed of, typically into a contamination unit. Various types of syringes are available in the market depending upon their usage
ANALYSIS OF COVID-19 REFURBISHED MEDICAL EQUIPMENT MARKET
Growth in global refurbished medical equipment market would be robust. It would reach a valuation of about USD 24 billion by the end of this period, creating rewarding opportunities of growth. And, it is quite pertinent to note here that a number of trends and drivers will underscore it. The on-going pandemic of COVID-19 is a particularly strong factor as hospitals across the world prepare themselves for tackling the ever-growing
IMPACT OF COVID-19 ON TAMIFLU (OSELTAMIVIR PHOSPHATE) MARKET
OTC Distribution Drives Tamiflu (Oseltamivir Phosphate) Market High prevalence of influenza and flu has created a demand for Tamiflu (Oseltamivir Phosphate). Thus, companies are entering into strategic deals to gain rights for over-the-counter (OTC) distribution of the medication. For instance, in July 2019, leading French multinational pharmaceutical company Sanofi entered into an agreement with Roche-a Swiss multinational healthcare company, to gain rights for over-the-counter distribution of Tamiflu in the U.S. Such

All 5 Releases


More Releases for SLE

Systemic Lupus Erythematous SLE Drugs Market Estimated to Flourish by 2025
Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis,
Systemic lupus erythematosus (SLE) Market Research Report : Forecast 2025
In terms of geography, North America accounts for the dominant share in terms of revenue owing to advancements in the treatment of systemic lupus erythematosus and rising awareness among people about the disease. Europe accounts for the second largest market in terms of revenue due to high incidence rate of SLE and increase in research activities in the field of systemic lupus erythematosus. The Asia Pacific market is also witnessing
Global Resuscitation Ventilators Market 2017 : Eternity, SIRIUSMED, Siare & SLE
The survey report by Market Research Store is an overview of the global Resuscitation Ventilators market. It covers all the recent trends including key developments in the global market in present and in future. Analyses of the global Resuscitation Ventilators market trends along with the projections of CAGRs (compound annual growth rates) are provided in the research report. Further, an evaluation of the history of the global market and the basic
Global Respiratory Devices Market-SLE Ltd, Teijin Pharma, Resmed, Weinmann
Global Respiratory Devices Market report 2017 is an in-depth research on the current situation of the Respiratory Devices industry. The Scope of the Respiratory Devices research report: The Global Respiratory Devices Market primarily includes a basic overview of the Respiratory Devices industry. It also includes Respiratory Devices definitions, classifications and applications. It segments the market by applications, types, regions, competitive players and also analyzes Respiratory Devices market size, business share and Respiratory
Systemic Lupus Erythematous SLE Drugs Market To Increase at Steady Growth Rate
Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis,
SuppreMol employs Protagen biomarkers in SLE study
Munich and Dortmund, Germany, August 2, 2011. SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, today announced a collaboration to identify therapy-related biomarkers in patients with Systemic Lupus Erythematosus (SLE). “We will use the unique biomarker portfolio of Protagen for the rapid identification of autoantibody signatures in the